Parkman Healthcare Partners’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $19.9M | Sell |
|
|||||
|
2025
Q2 | $20.9M | Sell |
|
|||||
|
2025
Q1 | $18.6M | Buy |
|
|||||
|
2024
Q4 | $15.8M | Sell |
|
|||||
|
2024
Q3 | $15M | Buy |
|
|||||
|
2024
Q2 | $15.9M | Sell |
|
|||||
|
2024
Q1 | $18.2M | Sell |
|
|||||
|
2023
Q4 | $18.5M | Buy |
|
|||||
|
2023
Q3 | $9.43M | Sell |
|
|||||
|
2023
Q2 | $13.2M | Sell |
|
|||||
|
2023
Q1 | $22M | Buy |
|
|||||
|
2022
Q4 | $13.9M | Sell |
|
|||||
|
2022
Q3 | $12.5M | Buy |
|
|||||
|
2022
Q2 | $8.34M | Buy |
|
|||||
|
2022
Q1 | $5.93M | Buy |
|
|||||
|
2020
Q4 | – | Sell |
|
|||||
|
2020
Q3 | $12.7M | Buy |
|
|||||
|
2020
Q2 | $14.8M | Sell |
|
|||||
|
2020
Q1 | $11.1M | Sell |
|
|||||
|
2019
Q4 | $16.7M | Buy |
|